NHS England strikes deal for ground-breaking CAR-T therapy in a new European first

Adult cancer patients in England will receive the new game-changing CAR-T therapy Yescarta® under the first negotiated deal of its kind struck in Europe.

Go to the profile of Jasmine Harris
Oct 08, 2018
0
0

Adult cancer patients in England will receive the game-changing CAR-T therapy Yescarta® (axicabtagene ciloleucel), under the first negotiated deal of its kind struck in Europe.

This is the first time adult patients will have access to CAR-T via the National Health Service (NHS), and follows a deal NHS England reached last month to make Kymriah® available for children and young people with B cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.

“CAR-T cell therapy is one of the most promising new treatments in a generation for lymphoma and leukaemia, and NHS patients will now be among the first in the world to benefit,” explained Simon Stevens, chief executive, NHS England (UK).

Read more on our sister site, Oncology Central.

Go to the profile of Jasmine Harris

Jasmine Harris

Digital Editor, Future Science Group

No comments yet.